Importantly, RAS/RTK mutations in hyperdiploid tumours were typically clonal, whereas in ERG-deleted ALL mutations were almost exclusively subclonal, suggesting the efficacy of RAS/RTK inhibitors will differ between subtypes. This evidence concerns the gene ERG and neoplasm.